A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles
- PMID: 40409324
- PMCID: PMC12308976
- DOI: 10.1016/S2468-1253(25)00069-X
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles
Erratum in
-
Correction to Lancet Gastroenterol Hepatol 2025; 10: 671-84.Lancet Gastroenterol Hepatol. 2025 Sep;10(9):e11. doi: 10.1016/S2468-1253(25)00241-9. Lancet Gastroenterol Hepatol. 2025. PMID: 40782814 No abstract available.
Abstract
The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development the elimination of viral hepatitis. Profiles from 33 countries and territories show progress, towards elimination of hepatitis B with 24 (73%) of them meeting the 2025 WHO interim target of 0·5% or less HBsAg prevalence in children younger than 5 years. 22 (67%) of countries and territories profiled have policies for universal hepatitis B birth-dose vaccination of newborns. Access to hepatitis B testing and treatment, including removing HBsAg screening and hepatitis B treatment patient co-payments and simplifying treatment algorithms, remains suboptimal, especially in low-income and middle-income countries and territories. Of the seven profiled countries and territories meeting the 60% WHO 2025 diagnosis coverage target, all but one (Rwanda) is a high-income country or territory. No country or territory has met the WHO 2025 treatment target of at least 50% of people living with hepatitis B receiving treatment. The profiles guide national planning and identify priorities for resource mobilisation to further accelerate hepatitis B elimination.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests CWS reports speaker honoraria from Gilead Sciences and Sanofi, and meeting travel support from Gilead Sciences. IW reports grants from Arena, AbbVie, and AstraZeneca, and honoraria from AstraZeneca and Roche. JVL reports grants to his institutions from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, MSD, Novo Nordisk, Pfizer, Roche Diagnostics, and Moderna unrelated to this work. JVL reports consulting fees from Echosens, Novovax, GSK, Novo Nordisk, Pfizer, and Prosciento unrelated to this work. JVL received lecture honoraria from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk, and Pfizer unrelated to this work. JVL participates in an advisory board for the project, Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (The QuickStart Study): a cluster randomised control trial – Australia, is in an unpaid leadership role with HIV Outcomes and Healthy Livers, Healthy Lives. LH-S, JM, and JWW report grant support to The Task Force for Global Health for the general support of the CGHE from Abbott, AbbVie, Dynavax, Gilead, John C Martin Foundation, Merck, Open Philanthropy, Pharco, Roche, Siemens, US Centers for Disease Control and Prevention, and Zydus Lifesciences. MB reports grants from Gilead Sciences, consulting fees from Gilead Sciences and GSK, and honoraria from Gilead Sciences and GSK. LAK reports research grants to her institution from Gilead Sciences. All other authors declare no competing interests.
Figures


References
-
- WHO. Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization, 2024. https://www.who.int/publications/i/item/9789240091672 (accessed Dec 20, 2024).
-
- WHO. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. World Health Organization, 2022. https://iris.who.int/bitstream/handle/10665/360348/9789240053779-eng.pdf... (accessed Sept 20, 2024).
-
- WHO. Interim guidance for country validation of viral hepatitis elimination. World Health Organization, 2021. https://iris.who.int/bitstream/handle/10665/341652/9789240028395-eng.pdf... (accessed Dec 19, 2024).
-
- WHO. Guidance for country validation of viral hepatitis elimination and path to elimination: technical report. World Health Organization. Geneva: World Health Organization, 2023. (accessed Dec 19, 2024).
-
- WHO. Global health sector strategies 2022–2030. World Health Organization, 2022. https://iris.who.int/bitstream/handle/10665/360348/9789240053779-eng.pdf... (accessed Sept 20, 2024).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous